Roberta Roncarati graduated with honors in Pharmaceutical Chemistry and Technology in 1997 at the University of Ferrara; PhD in Molecular Medicine (2009), she has been a CNR researcher since 2009. Dr. Roncarati worked from 1997 to 2004 in the United States, where she finalized her research program. She joined the laboratory of Prof. Antonio Giordano at Thomas Jefferson University, Philadelphia, for 1 year before moving to the laboratories of Prof. Carlo M. Croce at the Kimmel Cancer Institute, Philadelphia, where she studied the role of apoptotic genes (caspase-3 and Bcl2) in cardiovascular diseases in animal models, working in the team of Prof. Gianluigi Condorelli. In 1998, she started her second fellowship in the group of Prof. Luciano D’Adamio at Yeshiva University, Albert Einstein College of Medicine, Bronxn (NY), where she studied the role of Amyloid Precursor Protein in the development of Alzheimer’s disease in in vitro models. From 2000 to 2003, she carried out research and development activities at the laboratories of Aventis Pharmaceutical (Immunology Platform), Bridgwater(NJ), under the supervision of Dr Roland Kurrel. In 2004, she returned to Italy and worked at Tecnobios Prenatale Clinic, Bologna, where she carried out prenatal diagnosis research (Prof. Bovicelli). From 2006 to 2009, she worked at the ITB-CNR, Milan, focusing her interest in the identification of new mutations in familial and idiopathic cardiomyopathies using next-generation sequencing. Since 2010, she has been a researcher at the IRGB-CNR institute (UOS of Milan), where she is carrying out research in the genetics of cardiovascular diseases, using NGS approaches applied to the clinic. In 2013, she moved to the University of Ferrara (Prof. M. Negrini ), where she specialized in molecular genomics applied to cardiology and clinical oncology. She also gained experience in the study of early diagnostic markers, such as microRNAs, as regulators of gene expression in cardiovascular diseases and cancer, studying their expression profile in the plasma of affected patients. Over the last 3 years, she has focused her interest on the study of DNA methylationin liquid biopsies, using the NGS approaches, for the early diagnosis of lung cancer.